$HITC
Healthcare Integrated Technologies Inc. Stock $hitc

$hitc Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000149315224042789 Filed on October 29, 2024

Income Statement

Concept	2024 Q4	2024
Revenue		$322.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit		$82.05K
YoY Change
Gross Profit Margin		25.48%
Selling, General & Admin	$343.8K	$516.3K
YoY Change	149.09%	-23.46%
% of Gross Profit		629.21%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$670.2K	$1.066M
YoY Change	210.77%	10.82%
Operating Profit	-$670.2K	-$983.6K
YoY Change	210.77%	2.29%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$13.94K	$281.1K
YoY Change	8.51%	-182.45%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$684.1K	-$702.5K
YoY Change	199.4%	-46.06%
Net Earnings / Revenue		-218.16%
Basic Earnings Per Share	-$0.01	-$0.01
Diluted Earnings Per Share	-$0.01	-$0.01
COMMON SHARES
Basic Shares Outstanding	102.2M shares	70.05M shares
Diluted Shares Outstanding	83.44M shares	70.05M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$2.014M	$175.6K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$33.02K	$33.02K
Receivables		$14.00K
Other Receivables
Total Short-Term Assets	$2.267M	$222.6K
YoY Change	5628.58%	545.11%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$436.7K	$506.7K
YoY Change	-46.33%	-41.72%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$436.7K	$506.7K
YoY Change	-46.33%	-41.72%
TOTAL ASSETS
Total Short-Term Assets	$2.267M	$222.6K
Total Long-Term Assets	$436.7K	$506.7K
Total Assets	$2.703M	$729.3K
YoY Change	216.82%	-19.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$225.0K	$225.0K
YoY Change	0.0%	0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$225.0K	$225.0K
YoY Change	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities	$225.0K	$225.0K
Total Liabilities	$944.2K	$1.023M
YoY Change	-45.29%	-34.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.00M	-$16.31M
YoY Change	7.31%	4.5%
Common Stock	$18.54M	$16.02M
YoY Change	23.85%	7.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.759M	-$293.2K
YoY Change
Total Liabilities & Shareholders Equity	$2.703M	$729.3K
YoY Change	216.82%	-19.32%

Cashflow Statement

Concept	2024 Q4	2024
OPERATING ACTIVITIES
Net Income	-$684.1K	-$702.5K
YoY Change	199.4%	-46.06%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$378.7K	-$267.7K
YoY Change	12319.38%	152.09%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$550.0K
YoY Change		83.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.217M	$442.9K
YoY Change	79956.59%	232.68%
NET CHANGE
Cash From Operating Activities	-$378.7K	-$267.7K
Cash From Investing Activities
Cash From Financing Activities	$2.217M	$442.9K
Net Change In Cash	$1.838M	$175.2K
YoY Change	-656564.29%	-27467.34%
FREE CASH FLOW
Cash From Operating Activities	-$378.7K	-$267.7K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001584693
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023	HITC	Cost Of Contracts CostOfContracts		usd
CY2023	us-gaap	Gross Profit GrossProfit		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2024	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2024	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2024	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2024	HITC	Shares Issued For Note Amendment Fees SharesIssuedForNoteAmendmentFees		usd
CY2024	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2024	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2024	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2023Q3	HITC	Finite Lived Intangible Assets Reserve For Impairment FiniteLivedIntangibleAssetsReserveForImpairment		usd
CY2024Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent		usd
CY2024	HITC	Income Tax Reconciliation Derivatives IncomeTaxReconciliationDerivatives		usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-07-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	false
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Public Float EntityPublicFloat	4731503	usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	102204936	shares
CY2024	HITC	No Insider Trading Flag NoInsiderTradingFlag	true
CY2024	dei	Auditor Firm AuditorFirmId	910
CY2024	dei	Auditor Name AuditorName	Rodefer Moss & CO, PLLC
CY2024	dei	Auditor Location AuditorLocation	Johnson City,
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	175562	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	411	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	33022	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	34092	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	222584	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	34503	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	506743	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	869432	usd
CY2024Q3	us-gaap	Assets Assets	729327	usd
CY2023Q3	us-gaap	Assets Assets	903935	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16637	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	155143	usd
CY2024Q3	us-gaap	Liabilities Liabilities	1022522	usd
CY2023Q3	us-gaap	Liabilities Liabilities	1569803	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79853696	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79853696	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68016167	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68016167	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	79854	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	68016	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	15941603	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	14878282	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16314652	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15612166	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-293195	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-665868	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	729327	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	903935	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	322000	usd
CY2024	HITC	Cost Of Contracts CostOfContracts	239948	usd
CY2024	us-gaap	Gross Profit GrossProfit	82052	usd
CY2024	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	516280	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	657667	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	186643	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	287016	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	221919	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16885	usd
CY2024	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	140770	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	1065612	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	961568	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-983560	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-961568	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	55079	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	417341	usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	279903	usd
CY2024	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	56250	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	76451	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	281074	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-340890	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-702486	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1302458	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70048860	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70048860	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44050535	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44050535	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2427758	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1302458	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	300000	usd
CY2023	HITC	Stock Issued During Period Value New Issuance Of Shares Payment Of Accrued Expenses StockIssuedDuringPeriodValueNewIssuanceOfSharesPaymentOfAccruedExpenses	2053006	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	28750	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	187586	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	150000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	345006	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-665868	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-702486	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	550000	usd
CY2024	HITC	Stock Issued During Period Value New Issuance Of Shares Payment Of Accrued Expenses StockIssuedDuringPeriodValueNewIssuanceOfSharesPaymentOfAccruedExpenses	338516	usd
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	186643	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-293195	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-293195	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-702486	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1302458	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	221919	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16885	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	186643	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	287016	usd
CY2024	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	140770	usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	279903	usd
CY2024	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	56250	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	28750	usd
CY2023	HITC	Shares Issued For Note Amendment Fees SharesIssuedForNoteAmendmentFees	150000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	194395	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	76451	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1070	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2524	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	19455	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	91571	usd
CY2024	HITC	Accounts Payable And Accrued Expenses Related Party AccountsPayableAndAccruedExpensesRelatedParty	-34957	usd
CY2023	HITC	Accounts Payable And Accrued Expenses Related Party AccountsPayableAndAccruedExpensesRelatedParty	328464	usd
CY2024	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	250010	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	173101	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-267729	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106203	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	27560	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27560	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	550000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	300000	usd
CY2024	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	114989	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	584283	usd
CY2024	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	222109	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	151160	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	600000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	442880	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	133123	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	175151	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-640	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	411	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1051	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	175562	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	411	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	62069	usd
CY2024	HITC	Shares Issued For Payment Of Payroll Related Liabilities SharesIssuedForPaymentOfPayrollRelatedLiabilities	338516	usd
CY2023	HITC	Shares Issued For Payment Of Payroll Related Liabilities SharesIssuedForPaymentOfPayrollRelatedLiabilities	1581056	usd
CY2023	HITC	Shares Issued For Payment Of Items Included In Accounts Payable And Accrued Expenses Related Party SharesIssuedForPaymentOfItemsIncludedInAccountsPayableAndAccruedExpensesRelatedParty	471950	usd
CY2023	HITC	Shares Issued For Payment Of Convertible Debt SharesIssuedForPaymentOfConvertibleDebt	150000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	110664	usd
CY2023	HITC	Capital Expenditures From Stockbased Compensation CapitalExpendituresFromStockbasedCompensation	57990	usd
CY2023	HITC	Shares Issued For Payment Of Items Included In Accounts Payable And Accrued Expenses SharesIssuedForPaymentOfItemsIncludedInAccountsPayableAndAccruedExpenses	37586	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zZXE75QJWKgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. We base our estimates on experience and various other assumptions that are believed to be reasonable under the circumstances. We evaluate our estimates and assumptions on a regular basis and actual results may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z652P4loFDJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts may be reclassified to conform to current period presentation with no changes to previously reported net loss or stockholders’ deficit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14000	usd
CY2024	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zqYrf3qWEdQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Credit Risk</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially expose the Company to credit risk consist of demand deposits with a financial institution. The Company is exposed to credit risk on its cash and cash equivalents in the event of default by the financial institution to the extent account balances exceed the amount insured by the FDIC, which is $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20240731_zX9kqz57hNi7" title="Cash FDIC insured amount">250,000</span>. One (1) customer accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230801__20240731__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zSCWQ5ZpOVL9" title="Concentration risk percentage">100</span>% of our consolidated accounts receivable at July 31, 2024 and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230801__20240731__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--RevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zgQnWSgu0Fpa" title="Concentration risk percentage">100</span>% of our consolidated revenue for the year ended July 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	140770	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	506743	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	869432	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2024Q3	HITC	Contract Liabilities ContractLiabilities	0	usd
CY2023Q3	HITC	Contract Liabilities ContractLiabilities	0	usd
CY2024	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	9919	usd
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	6184	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-702486	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	801636	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-237044	usd
CY2024Q3	HITC	Finite Lived Intangible Assets Reserve For Impairment FiniteLivedIntangibleAssetsReserveForImpairment	-57849	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	506743	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	894647	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-25215	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	869432	usd
CY2024	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	140770	usd
CY2024	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	140770	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	221919	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16885	usd
CY2024	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P6Y
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	213282	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	213282	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4135	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4135	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4135	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	67774	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	506743	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	143073	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	16637	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	12070	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16637	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	155143	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	225000	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	225000	usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-147522	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-273516	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	39195	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	72451	usd
CY2023	HITC	Income Tax Reconciliation Derivatives IncomeTaxReconciliationDerivatives	-24768	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	107283	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	176139	usd
CY2024	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1044	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	158	usd
CY2024Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1057273	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	949990	usd
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1057273	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	949990	usd
CY2024Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	4940000	usd
CY2024	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	expiring in fiscal 2037
CY2024Q3	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2023Q3	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2282031	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	100000	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3100000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	2846093	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	1382031	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	664062	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	4000000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2282031	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79853696	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68016167	shares
CY2023Q3	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	4705900	usd
CY2024Q2	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	4705900	usd

Files In Submission

Name	View Source	Status
0001493152-24-042789-index-headers.html	Edgar Link	pending
0001493152-24-042789-index.html	Edgar Link	pending
0001493152-24-042789.txt	Edgar Link	pending
0001493152-24-042789-xbrl.zip	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex10-5_001.jpg	Edgar Link	pending
ex10-5_002.jpg	Edgar Link	pending
ex10-5_003.jpg	Edgar Link	pending
ex10-5_004.jpg	Edgar Link	pending
ex10-5_005.jpg	Edgar Link	pending
ex10-5_006.jpg	Edgar Link	pending
ex10-5_007.jpg	Edgar Link	pending
ex10-5_008.jpg	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex10-7_001.jpg	Edgar Link	pending
ex10-7_002.jpg	Edgar Link	pending
ex10-7_003.jpg	Edgar Link	pending
ex10-7_004.jpg	Edgar Link	pending
ex10-7_005.jpg	Edgar Link	pending
ex10-7_006.jpg	Edgar Link	pending
ex10-8.htm	Edgar Link	pending
ex10-8_001.jpg	Edgar Link	pending
ex10-8_002.jpg	Edgar Link	pending
ex10-8_003.jpg	Edgar Link	pending
ex10-8_004.jpg	Edgar Link	pending
ex10-8_005.jpg	Edgar Link	pending
ex10-8_006.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
hitc-20240731.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
hitc-20240731_pre.xml	Edgar Link	unprocessable
hitc-20240731_def.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hitc-20240731_cal.xml	Edgar Link	unprocessable
hitc-20240731_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HITC
Healthcare Integrated Technologies Inc. Stock $hitc

2024 Q4 Form 10-K Financial Statement

#000149315224042789 Filed on October 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HITC Healthcare Integrated Technologies Inc. Stock $hitc

2024 Q4 Form 10-K Financial Statement

#000149315224042789 Filed on October 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HITC
Healthcare Integrated Technologies Inc. Stock $hitc